Why the study?
Does benazepril improve functional class compared to hydrochlorothiazide in post-infarction patients with mild symptomatic heart failure?
Does benazepril improve functional class compared to hydrochlorothiazide in post-infarction patients with mild symptomatic heart failure?
Benazepril is superior to hydrochlorothiazide in improving functional class and global efficacy in patients with mild symptomatic heart failure post-myocardial infarction.
Answers are grounded in this paper and cite their sources.
Benazepril improves NYHA class over hydrochlorothiazide in post-MI mild HF; supports ACE inhibitor preference in this population.
The non-sulfhydryl selective angiotensin-converting enzyme inhibitor benazepril (20 mg daily) was compared with hydrochlorothiazide (50 mg daily) in post-infarction (6-24 months) patients with symptomatic (NYHA functional class 2) mild heart failure. No concomitant drug therapy was given. The study had a double-blind cross-over design with 3-month treatment periods. Both drugs were well tolerated, and both caused a similar reduction in systolic blood pressure. Heart rate was higher with the diuretic. Benazepril improved the NYHA functional class in 17 out of 29 (59%) patients, whereas one patient improved with hydrochlorothiazide (P = 0.0004). With regard to global efficacy score, benazepril was also superior. Thus, angiotensin-converting enzyme inhibitors may be superior to diuretics as first-choice therapy in symptomatic mild heart failure.
No takes yet. Share an insight, caveat, or question.
Nordrehaug et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: